ViaCyte, a San Diego CA-based regenerative medicine company, raised $45M in Series D funding.

The round, which brought total Series D to more than $115m, includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Capital Partners, Invus Group, Asymmetry Ventures, and Artis Ventures.

The company intends to use the funds to advance its portfolio of stem cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes. 

Led by Michael Yang, President and Chief Executive Officer, and Brittany Bradrick, Chief Financial Officer and Chief Operating Officer, ViaCyte is a regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation. The company’s first product candidates are being developed as potential long-term treatments for patients with type 1 diabetes  to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with such companies as CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California.

Source link